GO:0004826 phenylalanine-tRNA ligase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004826 phenylalanine-tRNA ligase activity catalyzes ATP + L-phenylalanine + tRNA(Phe) = AMP + diphosphate + L-phenylalanyl-tRNA(Phe), attaching phenylalanine to its cognate tRNA.
• The enzymes are phenylalanyl-tRNA synthetases, encoded by FARS2 (mitochondrial) and FARSA/FARSB (cytoplasmic), and are essential for translation [2,4].
• Biallelic FARS2 variants cause FARS2 deficiency, a nuclear gene-encoded Leigh syndrome spectrum disorder [1,2].
• Biallelic FARSA variants cause a fatal systemic disorder, showing that cytoplasmic phenylalanyl-tRNA synthetase is indispensable in humans.
• Phenylalanyl-tRNA synthetases can misaminoacylate tRNA(Phe) with 3,4-dihydroxy-L-phenylalanine, revealing substrate promiscuity relevant to disease and drug design.
• Tryptophan depletion can cause tryptophan-to-phenylalanine substitutants, linking phenylalanine availability and phenylalanyl-tRNA synthetase activity to proteome quality.
Description
Phenylalanine-tRNA ligase activity (GO:0004826) is the molecular function that attaches the amino acid L-phenylalanine to its cognate transfer RNA, tRNA(Phe), using ATP as an energy source. This reaction is a core step in protein synthesis: without charged tRNA(Phe), ribosomes cannot decode phenylalanine codons, and translation stalls or becomes error-prone. The activity is catalyzed by phenylalanyl-tRNA synthetases, which exist as cytoplasmic and mitochondrial enzymes in human cells [2,4]. Because the reaction is essential for both cytosolic and mitochondrial translation, defects in the corresponding genes cause severe human disease [1,2,4]. Researchers study GO:0004826 to understand translation fidelity, mitochondrial function, and the molecular basis of rare genetic disorders [1,2,4]. The term is also relevant to cancer and metabolic stress, where amino acid availability and tRNA charging influence cell survival and protein quality. This article summarizes the definition, mechanism, key genes, disease links, and experimental methods for studying phenylalanine-tRNA ligase activity.
phenylalanine-tRNA ligase activity At A Glance
| GO ID | GO:0004826 |
|---|---|
| GO term | phenylalanine-tRNA ligase activity |
| Ontology | molecular_function |
| Synonym | L-phenylalanine:tRNAPhe ligase (AMP-forming) activity; L-phenylalanyl-tRNA synthetase activity; phenylalanine translase activity; phenylalanine-tRNA synthetase activity; phenylalanyl-transfer ribonucleate synthetase activity; phenylalanyl-transfer RNA ligase activity; phenylalanyl-transfer RNA synthetase activity; phenylalanyl-tRNA ligase activity; phenylalanyl-tRNA synthetase activity |
| Major function | Charges tRNA(Phe) with L-phenylalanine using ATP, forming phenylalanyl-tRNA(Phe) for ribosomal protein synthesis |
| Reaction | ATP + L-phenylalanine + tRNA(Phe) = AMP + diphosphate + L-phenylalanyl-tRNA(Phe) |
| Cellular location | Cytoplasm and mitochondria (cytoplasmic and mitochondrial phenylalanyl-tRNA synthetases) [2,4] |
| Key human genes | FARSA, FARSB (cytoplasmic), FARS2 (mitochondrial) [2,4] |
| Disease relevance | FARS2 deficiency and FARSA-related fatal systemic disorder [1,2,4] |
What Is GO:0004826?
GO:0004826 phenylalanine-tRNA ligase activity is defined as the catalysis of the reaction ATP + L-phenylalanine + tRNA(Phe) = AMP + diphosphate + L-phenylalanyl-tRNA(Phe). In other words, it is the activity that charges tRNA(Phe) with phenylalanine, forming phenylalanyl-tRNA(Phe), which delivers phenylalanine to the ribosome during translation. The activity belongs to the molecular_function ontology and is also known as phenylalanyl-tRNA synthetase activity, phenylalanine-tRNA synthetase activity, and phenylalanyl-tRNA ligase activity.
Why Is phenylalanine-tRNA ligase activity Important in Cell Biology?
Phenylalanine-tRNA ligase activity is essential because it provides the only canonical route for incorporating phenylalanine into proteins, and its failure impairs both cytosolic and mitochondrial translation. In humans, biallelic mutations in FARS2 cause a Leigh syndrome spectrum disorder, and biallelic FARSA mutations cause a fatal systemic disorder, demonstrating that this activity is non-redundant for organismal survival [1,2,4]. The enzyme can also misaminoacylate tRNA(Phe) with 3,4-dihydroxy-L-phenylalanine, indicating that substrate selection is not absolute and may contribute to proteome damage under certain conditions. Additionally, tryptophan depletion can lead to tryptophan-to-phenylalanine substitutants, linking phenylalanine metabolism and phenylalanyl-tRNA synthetase activity to translational fidelity and stress responses. Therefore, GO:0004826 is a critical node at the intersection of translation, mitochondrial biology, and inherited disease.
• Essential for translation: charges tRNA(Phe) with phenylalanine, enabling decoding of phenylalanine codons.
• Mitochondrial function: FARS2 provides phenylalanyl-tRNA synthetase activity in mitochondria, supporting oxidative phosphorylation [1,2].
• Cytosolic translation: FARSA/FARSB form the cytoplasmic phenylalanyl-tRNA synthetase, required for general protein synthesis.
• Disease causation: FARS2 variants cause FARS2 deficiency and Leigh syndrome spectrum [1,2].
• Disease causation: FARSA variants cause a fatal systemic disorder.
• Translation fidelity: misaminoacylation with 3,4-dihydroxy-L-phenylalanine shows potential for non-canonical amino acid incorporation.
• Proteome quality: tryptophan-to-phenylalanine substitutants link amino acid availability to protein sequence integrity.
• Therapeutic target: understanding substrate recognition may aid drug design against bacterial or parasite enzymes [5,6].
• Research tool: kinetic studies of the E. coli enzyme provide a model for catalytic mechanism.
• Biomarker potential: amino acid depletion and tRNA charging stress are relevant to cancer and metabolic disease.
Molecular Mechanism of phenylalanine-tRNA ligase activity
Substrate binding and activation of phenylalanine
In simple terms: The enzyme first grabs phenylalanine and ATP, then activates phenylalanine by attaching AMP to it.
Phenylalanyl-tRNA synthetase binds L-phenylalanine and ATP, forming phenylalanyl-AMP (an aminoacyl-adenylate) with release of diphosphate. This two-step activation is typical of class II aminoacyl-tRNA synthetases and is required before the amino acid can be transferred to tRNA.
Transfer of phenylalanine to tRNA(Phe)
In simple terms: The activated phenylalanine is then moved onto the tRNA that reads phenylalanine codons.
The activated phenylalanyl-AMP is transferred to the 3' end of tRNA(Phe), forming phenylalanyl-tRNA(Phe) and releasing AMP. The enzyme recognizes specific identity elements in tRNA(Phe) to ensure correct pairing of amino acid and tRNA.
Proofreading and substrate discrimination
In simple terms: The enzyme has quality-control steps to avoid attaching the wrong amino acid.
Phenylalanyl-tRNA synthetases can misaminoacylate tRNA(Phe) with 3,4-dihydroxy-L-phenylalanine, showing that substrate discrimination is not perfect and that editing or proofreading mechanisms may be important. This has implications for translational fidelity and for engineering enzymes with altered specificity.
Cellular compartmentalization and complex formation
In simple terms: Different versions of the enzyme work in the cytoplasm and in mitochondria.
In human cells, FARS2 encodes the mitochondrial phenylalanyl-tRNA synthetase, while FARSA and FARSB encode subunits of the cytoplasmic enzyme [2,4]. The cytoplasmic enzyme is a heterotetramer, and mutations in either subunit can impair function and cause disease.
Regulation by amino acid availability
In simple terms: When amino acids are scarce, the cell adjusts tRNA charging and protein synthesis.
Amino acid depletion can alter tRNA charging and lead to misincorporation; for example, tryptophan depletion results in tryptophan-to-phenylalanine substitutants, indicating that phenylalanine-tRNA synthetase activity and phenylalanine pools influence proteome composition. This links GO:0004826 to stress-responsive translation control.
Key Genes Involved in GO:0004826 phenylalanine-tRNA ligase activity
The following genes encode proteins that carry out or regulate phenylalanine-tRNA ligase activity in humans and model organisms.
| Gene | Major Role | Research Relevance |
|---|---|---|
| FARSA | Cytoplasmic phenylalanyl-tRNA synthetase alpha subunit | Biallelic variants cause fatal systemic disorder; models for translation defects |
| FARSB | Cytoplasmic phenylalanyl-tRNA synthetase beta subunit | Part of the heterotetrameric cytoplasmic enzyme; candidate for similar disorders |
| FARS2 | Mitochondrial phenylalanyl-tRNA synthetase | Biallelic variants cause FARS2 deficiency and Leigh syndrome spectrum [1,2] |
| GCN2 (EIF2AK4) | Sensor of amino acid deprivation | Links tRNA charging stress to integrated stress response |
| ATR | DNA damage response kinase | Tyrosyl-tRNA synthetase-related pathways; relevant to stress signaling |
| YARS1 | Tyrosyl-tRNA synthetase | Comparative studies on aminoacyl-tRNA synthetase depletion |
| E. coli pheS | Phenylalanyl-tRNA synthetase alpha subunit | Model for kinetic and mechanistic studies |
| E. coli pheT | Phenylalanyl-tRNA synthetase beta subunit | Model for tRNA recognition and catalysis |
| tRNA(Phe) genes | Substrate for charging | Identity elements determine specificity [5,6] |
| Ribosome components | Translate charged tRNA(Phe) | Downstream effectors of phenylalanine incorporation |
| eIF2alpha | Translation initiation factor | Responds to amino acid stress |
| mTOR pathway | Regulates translation capacity | Integrates amino acid availability with protein synthesis |
| Mitochondrial ribosome proteins | Mitochondrial translation | Affected by FARS2 dysfunction [1,2] |
| Aminoacyl-tRNA synthetase complexes | Multi-synthetase complex | May modulate synthetase activity and localization |
| DARS2 | Mitochondrial aspartyl-tRNA synthetase | Related mitochondrial synthetase disease model |
| RARS2 | Mitochondrial arginyl-tRNA synthetase | Related mitochondrial synthetase disease model |
How Is phenylalanine-tRNA ligase activity Regulated?
Phenylalanine-tRNA ligase activity is regulated at multiple levels. Amino acid availability influences tRNA charging, and depletion of amino acids such as tryptophan can lead to misincorporation and stress responses. The integrated stress response, mediated by GCN2 and eIF2alpha, senses uncharged tRNA and downregulates global translation while activating stress genes. Mitochondrial phenylalanyl-tRNA synthetase (FARS2) is regulated by mitochondrial import and may be affected by mitochondrial dysfunction [1,2]. Additionally, tyrosyl-tRNA synthetase (YARS1) and its nuclear functions in DNA repair show that aminoacyl-tRNA synthetases can have regulatory roles beyond translation, suggesting similar moonlighting functions may exist for phenylalanyl-tRNA synthetases [7,8].
phenylalanine-tRNA ligase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| FARS2 | FARS2 deficiency; Leigh syndrome spectrum | Fars2 knockout or point-mutation mouse; patient fibroblasts [1,2] |
| FARSA | Fatal systemic disorder | Farsa knockout mouse; patient-derived iPSCs |
| FARSB | Candidate for aminoacyl-tRNA synthetase-related disorder | Farsb knockout or point-mutation cell models |
| YARS1 | Heart failure and DNA damage response | Yars1 depletion models; ATR pathway readouts |
| GCN2/EIF2AK4 | Amino acid stress response | Gcn2 knockout cells; tryptophan depletion |
FARS2 deficiency and Leigh syndrome spectrum
Biallelic mutations in FARS2 cause FARS2 deficiency, a nuclear gene-encoded Leigh syndrome spectrum disorder characterized by mitochondrial dysfunction and neurological impairment [1,2]. FARS2 encodes the mitochondrial phenylalanyl-tRNA synthetase, and loss of its activity impairs mitochondrial translation, leading to energy failure in high-demand tissues [1,2].
FARSA-related fatal systemic disorder
Biallelic variants in FARSA, encoding the cytoplasmic phenylalanyl-tRNA synthetase alpha subunit, cause a fatal systemic disorder with severe developmental and multi-organ defects. This demonstrates that cytoplasmic phenylalanyl-tRNA synthetase activity is essential for human development and survival.
Amino acid stress and proteome quality
Tryptophan depletion results in tryptophan-to-phenylalanine substitutants, linking amino acid availability and phenylalanine-tRNA synthetase activity to proteome quality and stress adaptation. This mechanism may be relevant to cancer and metabolic diseases where amino acid pools are altered.
Aminoacyl-tRNA synthetase biology in heart and neurons
Tyrosine and phenylalanine activate neuronal DNA repair, and tyrosyl-tRNA synthetase depletion affects transcription and stress resilience, indicating that aminoacyl-tRNA synthetases and their amino acid products influence DNA damage responses and tissue homeostasis [7,8]. These findings suggest broader roles for phenylalanine-related pathways in heart failure and neuronal function [7,8].
From phenylalanine-tRNA ligase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of FARS2 cause mitochondrial translation defects? | FARS2 knockout cell line (e.g., HEK293 or patient fibroblasts) [1,2] |
| Does a patient variant impair phenylalanyl-tRNA synthetase activity? | Point-mutation knock-in of FARSA or FARS2 variant |
| Can wild-type FARSA rescue disease phenotypes? | Knock-in of tagged FARSA for rescue and localization |
| Does overexpression of FARS2 protect against stress? | Overexpression cell model with mitochondrial stress [1,2] |
| What proteins interact with phenylalanyl-tRNA synthetase? | Tagged knock-in (e.g., FLAG-FARSA) for proteomics |
| How does amino acid depletion affect tRNA charging? | Knockout of GCN2 or eIF2alpha mutants with tryptophan depletion |
How to Study the phenylalanine-tRNA ligase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Aminoacylation assay | Formation of phenylalanyl-tRNA(Phe) | Enzyme kinetics and inhibitor testing |
| Ribo-seq | Ribosome occupancy and translation efficiency | Global translation changes upon synthetase loss |
| RNA-seq | Transcript abundance and stress gene expression | Integrated stress response activation |
| Proteomics | Protein abundance and misincorporation | Detection of tryptophan-to-phenylalanine substitutants |
| CRISPR knockout screening | Gene essentiality and synthetic lethality | Identifying modifiers of FARS2/FARSA phenotypes |
| Mitochondrial respirometry | Oxidative phosphorylation capacity | FARS2 deficiency models [1,2] |
| Immunofluorescence | Protein localization and mitochondrial morphology | Tagged FARSA/FARS2 knock-in cells |
| Kinetic stopped-flow | Catalytic rate constants | Mechanistic studies of bacterial enzyme |
Biochemical assays for tRNA charging
Phenylalanine-tRNA ligase activity can be measured by monitoring the formation of phenylalanyl-tRNA(Phe) using radiolabeled phenylalanine or by coupling the reaction to pyrophosphate release. Kinetic studies of the E. coli enzyme provide a framework for determining catalytic parameters.
Genetic and CRISPR screens
CRISPR knockout screens can identify genes required for viability in cells with impaired phenylalanyl-tRNA synthetase activity, revealing synthetic lethal interactions and compensatory pathways. Point-mutation knock-in models can test the functional impact of patient variants.
Transcriptomics and proteomics
RNA-seq and Ribo-seq can measure changes in translation efficiency and stress responses upon loss of phenylalanyl-tRNA synthetase activity. Proteomics can detect misincorporation events such as tryptophan-to-phenylalanine substitutants.
Imaging and mitochondrial function
Mitochondrial morphology and function can be assessed by fluorescence imaging and respirometry in FARS2-deficient cells [1,2]. Localization of tagged FARSA or FARS2 can be visualized to confirm compartment-specific roles.
How CRISPR Can Be Used to Study GO:0004826 phenylalanine-tRNA ligase activity
Knockout
CRISPR knockout of FARSA, FARSB, or FARS2 can abolish phenylalanine-tRNA ligase activity in the respective compartment, causing translation defects and, in the case of FARS2, mitochondrial dysfunction [1,2,4]. These models are useful for studying essentiality and compensatory pathways.
Point Mutation
Point-mutation knock-in of patient variants (e.g., in FARSA or FARS2) allows researchers to test whether specific amino acid changes impair catalytic activity or stability. Such models can reproduce disease-relevant phenotypes in isogenic cell lines.
Knock-in
Tagged knock-in of FARSA or FARS2 (e.g., with FLAG or GFP) enables localization, interaction, and rescue studies without altering endogenous regulation. This approach helps define the subcellular distribution and complex formation of phenylalanyl-tRNA synthetases.
Overexpression
Overexpression of wild-type or mutant FARSA/FARS2 can test gain-of-function effects, dominant-negative activity, or protection against stress [1,2]. Overexpression models are also useful for biochemical purification and structural studies.
How EDITGENE Supports phenylalanine-tRNA ligase activity Research
Researchers studying phenylalanine-tRNA ligase activity-related genes often need to determine whether a candidate gene is causally involved in translation, mitochondrial function, or disease. EDITGENE provides CRISPR-based cell models and screening services to accelerate this work.
Contact EDITGENE today to design your custom CRISPR model for phenylalanine-tRNA ligase activity research.
Frequently Asked Questions About phenylalanine-tRNA ligase activity
What is phenylalanine-tRNA ligase activity?
It is the molecular function that attaches L-phenylalanine to tRNA(Phe) using ATP, forming phenylalanyl-tRNA(Phe) for protein synthesis.
What genes are involved in phenylalanine-tRNA ligase activity?
The main human genes are FARSA and FARSB for the cytoplasmic enzyme and FARS2 for the mitochondrial enzyme [2,4].
What is the GO ID for phenylalanine-tRNA ligase activity?
The GO ID is GO:0004826.
What diseases are linked to phenylalanine-tRNA ligase activity?
FARS2 mutations cause FARS2 deficiency and Leigh syndrome spectrum, while FARSA mutations cause a fatal systemic disorder [1,2,4].
How is phenylalanine-tRNA ligase activity measured?
It can be measured by aminoacylation assays using radiolabeled phenylalanine or by coupling to pyrophosphate release.
Can phenylalanyl-tRNA synthetase misincorporate other amino acids?
Yes, it can misaminoacylate tRNA(Phe) with 3,4-dihydroxy-L-phenylalanine, indicating substrate promiscuity.
What is the role of FARS2 in mitochondria?
FARS2 encodes the mitochondrial phenylalanyl-tRNA synthetase, which is required for mitochondrial translation and energy production [1,2].
How does amino acid depletion affect phenylalanine-tRNA ligase activity?
Tryptophan depletion can lead to tryptophan-to-phenylalanine substitutants, linking amino acid availability to translation fidelity.
What model systems are used to study phenylalanine-tRNA ligase activity?
Common models include E. coli for kinetics, yeast for genetics, and human cell lines or mouse models for disease [1,2,4,6].
What CRISPR models are available for studying this activity?
Knockout, point-mutation knock-in, tagged knock-in, and overexpression models can be generated for FARSA, FARSB, and FARS2.
Conclusion
Phenylalanine-tRNA ligase activity (GO:0004826) is a fundamental molecular function required for translation in both cytoplasm and mitochondria. Its importance is underscored by severe human disorders caused by mutations in FARSA and FARS2, and by its potential role in amino acid stress and proteome quality [1,2,3,4]. Studying this activity with CRISPR models, biochemical assays, and omics methods will continue to reveal mechanisms of translation and disease.
References
- 1. Adam MP et al.. 1993. Nuclear Gene-Encoded Leigh Syndrome Spectrum Overview.. PMID: 26425749
- 2. Adam MP et al.. 1993. FARS2 Deficiency.. PMID: 30869852
- 3. Pataskar A et al.. 2022. Tryptophan depletion results in tryptophan-to-phenylalanine substitutants.. Nature 603(7902):721-727 PMID: 35264796
- 4. Kim SY et al.. 2022. Fatal systemic disorder caused by biallelic variants in FARSA.. Orphanet J Rare Dis 17(1):306 PMID: 35918773
- 5. Moor N et al.. 2011. Bacterial and eukaryotic phenylalanyl-tRNA synthetases catalyze misaminoacylation of tRNA(Phe) with 3,4-dihydroxy-L-phenylalanine.. Chem Biol 18(10):1221-9 PMID: 22035791
- 6. Bartmann P et al.. 1975. L-phenylalanine:tRNA ligase of Escherichia coli K10. A rapid kinetic investigation of the catalytic reaction.. Biochemistry 14(22):4777-86 PMID: 1101957
- 7. Jhanji M et al.. 2025. Tyrosine and Phenylalanine Activate Neuronal DNA Repair but Exhibit Opposing Effects on Global Transcription and Adult Female Mice Are Resilient to TyrRS/YARS1 Depletion.. IUBMB Life 77(6):e70030 PMID: 40476370
- 8. Zhao R et al.. 2023. Nuclear ATR lysine-tyrosylation protects against heart failure by activating DNA damage response.. Cell Rep 42(4):112400 PMID: 37071536
